Ophthalmic drug discovery: Novel targets and mechanisms for retinal diseases and glaucoma

Nature Reviews Drug Discovery

Volumn 11, Issue 7, 2012, Pages 541-559

  Zhang, Kang ^a,b,c   Zhang, Liangfang ^c,d   Weinreb, Robert N ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACU 4429; AFLIBERCEPT; AGENTS ACTING ON THE EYE; AL 78898A; ANGIOGENESIS INHIBITOR; ANTIOXIDANT; ARC 1905; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BEVACIZUMAB; CARBONATE DEHYDRATASE INHIBITOR; CHOLINERGIC RECEPTOR STIMULATING AGENT; COMPLEMENT INHIBITOR; ECULIZUMAB; EVEROLIMUS; FCFD 4514S; FENRETINIDE; PALOMID 529; PAZOPANIB; PEGAPTANIB; PF 04523655; PF 655; PILOCARPINE; POT 4; PROSTAGLANDIN F RECEPTOR DERIVATIVE; PROSTAGLANDIN RECEPTOR; RANIBIZUMAB; RAPAMYCIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; VISUAL CYCLE INHIBITOR; VITAMIN;

BIOTECHNOLOGY; BROW ACHE; CLINICAL TRIAL (TOPIC); COLOR VISION DEFECT; CORNEA NEOVASCULARIZATION; DARK ADAPTATION; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ENCAPSULATED CELL TECHNOLOGY; EYE DISEASE; EYE PAIN; GENE THERAPY; GENOMICS; GEOGRAPHIC ATROPHY; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; INTRAOCULAR PRESSURE ABNORMALITY; LASER COAGULATION; LOW LEVEL LASER THERAPY; MIOSIS; MYOPIA; NANOMEDICINE; NIGHT BLINDNESS; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINA DISEASE; RETINA MACULA AGE RELATED DEGENERATION; RETINA VEIN OCCLUSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VISION DIMMING; VISUAL DISORDER;

ADMINISTRATION, OPHTHALMIC; ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DISCOVERY; GENE THERAPY; GLAUCOMA; HUMANS; OPHTHALMIC SOLUTIONS; RETINAL DISEASES;

EID: 84863225073     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd3745     Document Type: Review

References (205)

1. Rein, D. B. et al. The economic burden of major adult visual disorders in the United States. Arch. Ophthalmol. 124, 1754-1760 (2006). (Pubitemid 44920172)
2. Gaudana, R., Ananthula, H. K., Parenky, A. & Mitra, A. K. Ocular drug delivery. AAPS J. 12, 348-360 (2010).
3. Jager, R. D., Mieler, W. F. & Miller, J. W. Age-related macular degeneration. N. Engl. J. Med. 358, 2606-2617 (2008).
4. Zarbin, M. A. & Rosenfeld, P. J. Pathway-based therapies for age-related macular degeneration: an integrated survey of emerging treatment alternatives. Retina 30, 1350-1367 (2010).
5. Yehoshua, Z., Rosenfeld, P. J. & Albini, T. A. Current clinical trials in dry AMD and the definition of appropriate clinical outcome measures. Semin. Ophthalmol. 26, 167-180 (2011).
6. Weinreb, R. N. & Khaw, P. T. Primary open-angle glaucoma. Lancet 363, 1711-1720 (2004). (Pubitemid 38670330)
7. Haddad, S., Chen, C. A., Santangelo, S. L. & Seddon, J. M. The genetics of age-related macular degeneration: a review of progress to date. Surv. Ophthalmol. 51, 316-363 (2006). (Pubitemid 43970736)
8. Rattner, A. & Nathans, J. Macular degeneration: recent advances and therapeutic opportunities. Nature Rev. Neurosci. 7, 860-872 (2006). (Pubitemid 44624178)
9. Penfold, P. L., Killingsworth, M. C. & Sarks, S. H. Senile macular degeneration: the involvement of immunocompetent cells. Graefes Arch. Clin. Exp. Ophthalmol. 223, 69-76 (1985). (Pubitemid 15051681)
10. Klein, R., Klein, B. E. & Linton, K. L. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99, 933-943 (1992).
11. Vingerling, J. R. et al. The prevalence of age-related maculopathy in the Rotterdam study. Ophthalmology 102, 205-210 (1995).
12. Hageman, G. S. et al. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res. 20, 705-732 (2001). (Pubitemid 32918285)
13. Kaplan, H. J., Leibole, M. A., Tezel, T. & Ferguson,T. A. Fas ligand (CD95 ligand) controls angiogenesis beneath the retina. Nature Med. 5, 292-297 (1999). (Pubitemid 29124364)
14. Krzystolik, M. G. et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch. Ophthalmol. 120, 338-346 (2002). (Pubitemid 34250056)
15. Okamoto, N. et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am. J. Pathol. 151, 281-291 (1997).
16. Friedman, D. S. et al. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 122, 564-572 (2004). (Pubitemid 38456293)
17. Dithmar, S. et al. Murine high-fat diet and laser photochemical model of basal deposits in Bruch membrane. Arch. Ophthalmol. 119, 1643-1649 (2001). (Pubitemid 33035706)
18. Green, W. R. & Key, S. N. Senile macular degeneration: a histopathologic study. Trans. Am. Ophthalmol. Soc. 75, 180-254 (1977).
19. Hageman, G. S. & Mullins, R. F. Molecular composition of drusen as related to substructural phenotype. Mol. Vis. 5, 28 (1999).
20. Kvanta, A., Algvere, P. V., Berglin, L. & Seregard, S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci. 37, 1929-1934 (1996). (Pubitemid 26324159)
21. Hageman, G. S. et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl Acad. Sci. USA 102, 7227-7232 (2005). (Pubitemid 40696361)
22. Mullins, R. F., Russell, S. R., Anderson, D. H. & Hageman, G. S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. FASEB J. 14, 835-846 (2000). (Pubitemid 30241660)
23. Mullins, R. F., Aptsiauri, N. & Hageman, G. S. Structure and composition of drusen associated with glomerulonephritis: implications for the role of complement activation in drusen biogenesis. Eye 15, 390-395 (2001). (Pubitemid 32600863)
24. Anderson, R. E. et al. Low docosahexaenoic acid levels in rod outer segments of rats with P23H and S334ter rhodopsin mutations. Mol. Vis. 8, 351-358 (2002). (Pubitemid 36153625)
25. Johnson, L. V., Leitner, W. P., Staples, M. K. & Anderson, D. H. Complement activation and inflammatory processes in Drusen formation and age related macular degeneration. Exp. Eye Res. 73, 887-896 (2001). (Pubitemid 34112114)
26. Crabb, J. W. et al. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 14682-14687 (2002). (Pubitemid 35334544)
27. Yang, Z. et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314, 992-993 (2006). (Pubitemid 44749944)
28. Gehrs, K. M., Anderson, D. H., Johnson, L. V. & Hageman, G. S. Age-related macular degeneration-emerging pathogenetic and therapeutic concepts. Ann. Med. 38, 450-471 (2006). (Pubitemid 44767496)
29. Kaneko, H. et al. DICER1 deficit induces Alu RNA toxicity in age-related macular degeneration. Nature 471, 325-330 (2011).
30. Weismann, D. et al. Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. Nature 478, 76-81 (2011).
31. Nozaki, M. et al. Drusen complement components C3a and C5a promote choroidal neovascularization. Proc. Natl Acad. Sci. USA 103, 2328-2333 (2006). (Pubitemid 43271669)
32. Ferrara, N. Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy. Nature Med. 16, 1107-1111 (2010).
33. Aiello, L. P. et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331, 1480-1487 (1994). (Pubitemid 24356306)
34. Adamis, A. P. et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118, 445-450 (1994). (Pubitemid 24307211)
35. Hollyfield, J. G. et al. Oxidative damage-induced inflammation initiates age-related macular degeneration. Nature Med. 14, 194-198 (2008). (Pubitemid 351214555)
36. Tuo, J. et al. Murine ccl2/cx3cr1 deficiency results in retinal lesions mimicking human age-related macular degeneration. Invest. Ophthalmol. Vis. Sci. 48, 3827-3836 (2007). (Pubitemid 351261124)
37. Karan, G. et al. Lipofuscin accumulation, abnormal electrophysiology, and photoreceptor degeneration in mutant ELOVL4 transgenic mice: a model for macular degeneration. Proc. Natl Acad. Sci. USA 102, 4164-4169 (2005). (Pubitemid 40388573)
38. Maeda, A., Maeda, T., Golczak, M. & Palczewski, K. Retinopathy in mice induced by disrupted all-trans-retinal clearance. J. Biol. Chem. 283, 26684-26693 (2008).
39. Yang, Z. et al. Mutant prominin 1 found in patients with macular degeneration disrupts photoreceptor disk morphogenesis in mice. J. Clin. Invest. 118, 2908-2916 (2008).
40. Jones, A. et al. Increased expression of multifunctional serine protease, HTRA1, in retinal pigment epithelium induces polypoidal choroidal vasculopathy in mice. Proc. Natl Acad. Sci. USA 108, 14578-14583 (2011).
41. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch. Ophthalmol. 119, 1417-1436 (2001).
42. Varma, R. et al. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. Ophthalmology 114, 1332-1340 (2007). (Pubitemid 47001493)
43. Patel, S., Chen, H., Tinkham, N. H. & Zhang, K. Genetic susceptibility of diabetic retinopathy. Curr. Diab. Rep. 8, 257-262 (2008).
44. Yucel, Y. H., Zhang, Q., Weinreb, R. N., Kaufman, P. L. & Gupta, N. Effects of retinal ganglion cell loss on magno-, parvo-, koniocellular pathways in the lateral geniculate nucleus and visual cortex in glaucoma. Prog. Retin. Eye Res. 22, 465-481 (2003). (Pubitemid 36556145)
45. Quigley, H. A. Glaucoma. Lancet 377, 1367-1377 (2011).
46. Resnikoff, S. et al. Global data on visual impairment in the year 2002. Bull. World Health Organ. 82, 844-851 (2004). (Pubitemid 39573742)
47. Weinreb, R. N. & Harris, A. (eds) Ocular Blood Flow in Glaucoma (Kugler Publications Amsterdam, 2009).
48. Weinreb, R. N. et al. Risk assessment in the management of patients with ocular hypertension. Am. J. Ophthalmol. 138, 458-467 (2004). (Pubitemid 39208574)
49. Brown, D. M. et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006). (Pubitemid 44511558)
50. Rosenfeld, P. J. et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006). (Pubitemid 44511557)
51. Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908 (2011).
52. Rich, R. M. et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 26, 495-511 (2006). (Pubitemid 44620390)
53. Shih, T. Y., Gaydos, C. A., Rothman, R. E. & Hsieh, Y. H. Poor provider adherence to the Centers for Disease Control and Prevention treatment guidelines in US emergency department visits with a diagnosis of pelvic inflammatory disease. Sex Transm. Dis. 38, 299-305 (2011).
54. Zhang, M. et al. A Phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 118, 672-678 (2011).
55. Nguyen, Q. D. et al. A Phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 113, 1522.e1-1522.e14 (2006).
56. Brown, D. M. et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a Phase III study. Ophthalmology 117, 1124-1133 (2010).
57. Elman, M. J. et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117, 1064-1077 (2010).
58. Elman, M. J. et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118, 609-614 (2011).
59. Migdal, C. Glaucoma medical treatment: philosophy, principles and practice. Eye 14, 515-518 (2000). (Pubitemid 30479755)
60. Medeiros, F. A. & Weinreb, R. N. Medical backgrounders: glaucoma. Drugs Today 38, 563-570 (2002).
61. Sagara, T. et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outflow pathway. Arch. Ophthalmol. 117, 794-801 (1999). (Pubitemid 29265042)
62. Liu, J. H., Kripke, D. F. & Weinreb, R. N. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure. Am. J. Ophthalmol. 138, 389-395 (2004). (Pubitemid 39208565)
63. Nathanson, J. A. Human ciliary process adrenergic receptor: pharmacological characterization. Invest. Ophthalmol. Vis. Sci. 21, 798-804 (1981). (Pubitemid 12250374)
64. Liu, J. H., Medeiros, F. A., Slight, J. R. & Weinreb, R. N. Comparing diurnal and nocturnal effects of brinzolamide and timolol on intraocular pressure in patients receiving latanoprost monotherapy. Ophthalmology 116, 449-454 (2009).
65. Liu, J. H., Medeiros, F. A., Slight, J. R. & Weinreb, R. N. Diurnal and nocturnal effects of brimonidine monotherapy on intraocular pressure. Ophthalmology 117, 2075-2079 (2010).
66. Toris, C. B., Gleason, M. L., Camras, C. B. & Yablonski, M. E. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch. Ophthalmol. 113, 1514-1517 (1995).
67. Hernandez, M., Urcola, J. H. & Vecino, E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp. Eye Res. 86, 798-806 (2008).
68. Edwards, A. O. et al. Complement factor H polymorphism and age-related macular degeneration. Science 308, 421-424 (2005). (Pubitemid 40530082)
69. Haines, J. L. et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308, 419-421 (2005). (Pubitemid 40530081)
70. Klein, R. J. et al. Complement factor H polymorphism in age-related macular degeneration. Science 308, 385-389 (2005). (Pubitemid 40530070)
71. Li, M. et al. CFH haplotypes without the Y402H coding variant show strong association with susceptibility to age-related macular degeneration. Nature Genet. 38, 1049-1054 (2006). (Pubitemid 44325931)
72. Maller, J. et al. Common variation in three genes, including a noncoding variant in CFH, strongly influences risk of age-related macular degeneration. Nature Genet. 38, 1055-1059 (2006). (Pubitemid 44325932)
73. Yates, J. R. et al. Complement C3 variant and the risk of age-related macular degeneration. N. Engl. J. Med. 357, 553-561 (2007). (Pubitemid 47236280)
74. Fagerness, J. A. et al. Variation near complement factor I is associated with risk of advanced AMD. Eur. J. Hum. Genet. 17, 100-104 (2009).
75. Cousins, S. W. & the Ophthotech Study Group. Targeting complement factor 5 in combination with vascular endothelial growth factor (VEGF) inhibition for neovascular age related macular degeneration (AMD): results of a Phase 1 study. Invest. Ophthalmol. Vis. Sci. 51, e-Abstract 1251 (2010).
76. Mata, N. L., Weng, J. & Travis, G. H. Biosynthesis of a major lipofuscin fluorophore in mice and humans with ABCR-mediated retinal and macular degeneration. Proc. Natl Acad. Sci. USA 97, 7154-7159 (2000). (Pubitemid 30431433)
77. Sparrow, J. R., Nakanishi, K. & Parish, C. A. The lipofuscin fluorophore A2E mediates blue light-induced damage to retinal pigmented epithelial cells. Invest. Ophthalmol. Vis. Sci. 41, 1981-1989 (2000). (Pubitemid 30354376)
78. Kubota, R. et al. Safety and effect on rod function of ACU-4429, a novel small-molecule visual cycle modulator. Retina 32, 183-188 (2012).
79. Weng, J. et al. Insights into the function of Rim protein in photoreceptors and etiology of Stargardt's disease from the phenotype in abcr knockout mice. Cell 98, 13-23 (1999). (Pubitemid 29331192)
80. Land, S. C. & Tee, A. R. Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J. Biol. Chem. 282, 20534-20543 (2007). (Pubitemid 47100043)
81. Brafman, A. et al. Inhibition of oxygen-induced retinopathy in RTP801-deficient mice. Invest. Ophthalmol. Vis. Sci. 45, 3796-3805 (2004). (Pubitemid 39298599)
82. Kleinman, M. E. et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature 452, 591-597 (2008). (Pubitemid 351483358)
83. Hornung, V. et al. Sequence-specific potent induction of IFN-α by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nature Med. 11, 263-270 (2005). (Pubitemid 40460553)
84. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H. & Williams, B. R. Activation of the interferon system by short-interfering RNAs. Nature Cell Biol. 5, 834-839 (2003). (Pubitemid 37087172)
85. Dawson, D. W. et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285, 245-248 (1999). (Pubitemid 29329995)
86. Bhutto, I. A. et al. Reduction of endogenous angiogenesis inhibitors in Bruch's membrane of the submacular region in eyes with age-related macular degeneration. Arch. Ophthalmol. 126, 670-678 (2008). (Pubitemid 351679563)
87. Holekamp, N. M., Bouck, N. & Volpert, O. Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration. Am. J. Ophthalmol. 134, 220-227 (2002). (Pubitemid 34831826)
88. Maclachlan, T. K. et al. Preclinical safety evaluation of AAV2-sFLT01-a gene therapy for age-related macular degeneration. Mol. Ther. 19, 326-334 (2011).
89. Kendall, R. L. & Thomas, K. A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl Acad. Sci. USA 90, 10705-10709 (1993). (Pubitemid 23347111)
90. Ambati, B. K. et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443, 993-997 (2006). (Pubitemid 44646176)
91. Ferrara, N., Gerber, H. P. & LeCouter, J. The biology of VEGF and its receptors. Nature Med. 9, 669-676 (2003). (Pubitemid 36749215)
92. Takeda, A. et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460, 225-230 (2009).
93. Takahashi, K., Saishin, Y., King, A. G., Levin, R. & Campochiaro, P. A. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch. Ophthalmol. 127, 494-499 (2009).
94. LaVail, M. M. et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest. Ophthalmol. Vis. Sci. 39, 592-602 (1998).
95. Palanki, M. S. et al. Development of prodrug 4-chloro-3-(5-methyl-3-{[4- (2-pyrrolidin-1-ylethoxy) phenyl]amino}-1,2,4-benzotria zin-7-yl)phenyl benzoate (TG100801): a topically administered therapeutic candidate in clinical trials for the treatment of age-related macular degeneration. J. Med. Chem. 51, 1546-1559 (2008). (Pubitemid 351438839)
96. Heeschen, C., Weis, M., Aicher, A., Dimmeler, S. & Cooke, J. P. A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors. J. Clin. Invest. 110, 527-536 (2002). (Pubitemid 34919707)
97. Kiuchi, K. et al. Mecamylamine suppresses basal and nicotine-stimulated choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 49, 1705-1711 (2008).
98. Campochiaro, P. A. et al. Topical mecamylamine for diabetic macular edema. Am. J. Ophthalmol. 149, 839-851 (2010).
99. Ozaki, H., Hla, T. & Lee, M. J. Sphingosine-1-phosphate signaling in endothelial activation. J. Atheroscler. Thromb. 10, 125-131 (2003).
100. Watterson, K. R., Lanning, D. A., Diegelmann, R. F. & Spiegel, S. Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen. 15, 607-616 (2007). (Pubitemid 47495881)
101. Caballero, S. et al. Anti-sphingosine-1-phosphate monoclonal antibodies inhibit angiogenesis and sub-retinal fibrosis in a murine model of laser-induced choroidal neovascularization. Exp. Eye Res. 88, 367-377 (2009).
102. Xie, B. et al. Blockade of sphingosine-1-phosphate reduces macrophage influx and retinal and choroidal neovascularization. J. Cell Physiol. 218, 192-198 (2009).
103. Orecchia, A. et al. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the α5β1 integrin. J. Cell Sci. 116, 3479-3489 (2003). (Pubitemid 37063392)
104. Zahn, G. et al. Preclinical evaluation of the novel small-molecule integrin α5β1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularization. Arch. Ophthalmol. 127, 1329-1335 (2009).
105. Nirmalan, P. K. et al. Relationship between vision impairment and eye disease to vision-specific quality of life and function in rural India: the Aravind Comprehensive Eye Survey. Invest. Ophthalmol. Vis. Sci. 46, 2308-2312 (2005). (Pubitemid 43119473)
106. Pettit, G. R. et al. Antineoplastic agents 322. synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des. 10, 299-309 (1995).
107. Dark, G. G. et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res. 57, 1829-1834 (1997). (Pubitemid 27209705)
108. Nambu, H., Nambu, R., Melia, M. & Campochiaro, P. A. Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 3650-3655 (2003). (Pubitemid 36909807)
109. Griggs, J. et al. Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4. Am. J. Pathol. 160, 1097-1103 (2002). (Pubitemid 34224596)
110. Benjamin, L. E., Hemo, I. & Keshet, E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 125, 1591-1598 (1998). (Pubitemid 28256727)
111. Jo, N. et al. Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization. Am. J. Pathol. 168, 2036-2053 (2006). (Pubitemid 43825322)
112. Boyer, D. S. & the Ophthotech Anti-PDGF in AMD Study Group. Combined inhibition of platelet derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD)-results of a Phase 1 study. Invest. Ophthalmol. Vis. Sci. 50, e-Abstract 1260 (2009).
113. Sit, A. J., Weinreb, R. N., Crowston, J. G., Kripke, D. F. & Liu, J. H. Sustained effect of travoprost on diurnal and nocturnal intraocular pressure. Am. J. Ophthalmol. 141, 1131-1133 (2006). (Pubitemid 43831052)
114. Liu, J. H. & Weinreb, R. N. Monitoring intraocular pressure for 24 h. Br. J. Ophthalmol. 95, 599-600 (2011).
115. Coue, M., Brenner, S. L., Spector, I. & Korn, E. D. Inhibition of actin polymerization by latrunculin A. FEBS Lett. 213, 316-318 (1987). (Pubitemid 17043914)
116. Peterson, J. A. et al. Latrunculins' effects on intraocular pressure, aqueous humor flow, and corneal endothelium. Invest. Ophthalmol. Vis. Sci. 41, 1749-1758 (2000). (Pubitemid 30354346)
117. Chen, J., Runyan, S. A. & Robinson, M. R. Novel ocular antihypertensive compounds in clinical trials. Clin. Ophthalmol. 5, 667-677 (2011).
118. Rao, P. V., Deng, P. F., Kumar, J. & Epstein, D. L. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Invest. Ophthalmol. Vis. Sci. 42, 1029-1037 (2001). (Pubitemid 32289800)
119. Honjo, M. The possibility of selective Rho-associated kinase (ROCK) inhibitors as a medical treatment for glaucoma. [Article in Japanese] Nihon Ganka Gakkai Zasshi 113, 1071-1081 (2009).
120. Williams, R. D., Novack, G. D., van Haarlem, T. & Kopczynski, C. Ocular hypotensive effect of the Rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol. 152, 834-841 (2011).
121. Wirostko B. M., Umeno, H., Hsu, H. H. & Kengatharan, M. Safety and efficacy of a novel topical Rho kinase inhibitor ATS907 in normotensive cynomolgus monkeys. Invest. Ophthalmol. Vis. Sci. 52, e-Abstract 3096 (2011).
122. Yamamoto, T., Abe, H., Kuwayama, Y., Tanihara, H. & Araie, M. Efficacy and safety of the Rho kinase inhibitor, K-115, over 24 hours in patients with primary open-angle glaucoma and ocular hypertension. Invest. Ophthalmol. Vis. Sci. 52, e-Abstract 216 (2011).
123. Mizuno, K. et al. Ocular hypotensive mechanism of K-115, a Rho-kinase inhibitor, and Rho-kinase expression in the eye. Invest. Ophthalmol. Vis. Sci. 52, e-Abstract 237 (2011).
124. Sugiyama, T. et al. Effects of fasudil, a Rho-associated protein kinase inhibitor, on optic nerve head blood flow in rabbits. Invest. Ophthalmol. Vis. Sci. 52, 64-69 (2011).
125. Honjo, M. et al. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest. Ophthalmol. Vis. Sci. 48, 5549-5557 (2007). (Pubitemid 351260856)
126. Tian, B., Gabelt, B. T., Crosson, C. E. & Kaufman, P. L. Effects of adenosine agonists on intraocular pressure and aqueous humor dynamics in cynomolgus monkeys. Exp. Eye Res. 64, 979-989 (1997). (Pubitemid 27314773)
127. Wang, R. F., Podos, S. M., Mittag, T. W. & Yokoyoma, T. Effect of CS-088, an angiotensin AT1 receptor antagonist, on intraocular pressure in glaucomatous monkey eyes. Exp. Eye Res. 80, 629-632 (2005). (Pubitemid 40602963)
128. Chien, F. Y., Wang, R. F., Mittag, T. W. & Podos, S. M. Effect of WIN 55212-2, a cannabinoid receptor agonist, on aqueous humor dynamics in monkeys. Arch. Ophthalmol. 121, 87-90 (2003). (Pubitemid 36401772)
129. Hepler, R. S. & Frank, I. R. Marihuana smoking and intraocular pressure. JAMA 217, 1392 (1971).
130. Ruz, V., Moreno-Montañés, J., Sadaba, B., González, V. & Jiménez, A. I. Phase I study with a new siRNA: SYL040012. Tolerance and effect on intraocular pressure. Invest. Ophthalmol. Vis. Sci. 52, e-Abstract 223 (2011).
131. Schachar, R. A., Raber, S., Courtney, R. & Zhang, M. A Phase 2, randomized, dose-response trial of taprenepag isopropyl (PF-04217329) versus latanoprost 0.005% in open-angle glaucoma and ocular hypertension. Curr. Eye Res. 36, 809-817 (2011).
132. Schachar, R. A., Raber, S., Courtney, R., Zhang, M. & Bosworth, C. Dose-escalating, double-masked, vehicle-controlled trial of the IOP-reducing effect of the EP2 agonist PF-04217329. Invest. Ophthalmol. Vis. Sci. 51, e-Abstract 175 (2010).
133. Goldberg, D. F. & Williams, R. A Phase 2 study evaluating safety and efficacy of the latanoprost punctal plug delivery system (L-PPDS) in subjects with ocular hypertension (OH) or open-angle glaucoma (OAG). Invest. Ophthalmol. Vis. Sci. 53, e-Abstract 5095 (2012).
134. Clark, A. F. & Yorio, T. Ophthalmic drug discovery. Nature Rev. Drug Discov. 2, 448-459 (2003). (Pubitemid 37361726)
135. Mauler, F. & Horvath, E. Neuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury. J. Cereb. Blood Flow Metab. 25, 451-459 (2005).
136. Ramos, A. J. et al. The 5HT1A receptor agonist, 8-OH-DPAT, protects neurons and reduces astroglial reaction after ischemic damage caused by cortical devascularization. Brain Res. 1030, 201-220 (2004). (Pubitemid 39574953)
137. Adayev, T., Ray, I., Sondhi, R., Sobocki, T. & Banerjee, P. The G protein-coupled 5-HT1A receptor causes suppression of caspase-3 through MAPK and protein kinase Cα. Biochim. Biophys. Acta 1640, 85-96 (2003). (Pubitemid 36369641)
138. Hsiung, S. C., Tamir, H., Franke, T. F. & Liu, K. P. Roles of extracellular signal-regulated kinase and Akt signaling in coordinating nuclear transcription factor-κB-dependent cell survival after serotonin 1A receptor activation. J. Neurochem. 95, 1653-1666 (2005). (Pubitemid 41804062)
139. Collier, R. J. et al. Agonists at the serotonin receptor (5-HT1A) protect the retina from severe photo-oxidative stress. Invest. Ophthalmol. Vis. Sci. 52, 2118-2126 (2011).
140. Wen, R., Cheng, T., Li, Y., Cao, W. & Steinberg, R. H. α2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J. Neurosci. 16, 5986-5992 (1996). (Pubitemid 26313974)
141. Johnson, L. V. et al. The Alzheimer's Aβ-peptide is deposited at sites of complement activation in pathologic deposits associated with aging and age-related macular degeneration. Proc. Natl Acad. Sci. USA 99, 11830-11835 (2002). (Pubitemid 34994484)
142. Ding, J. D. et al. Targeting age-related macular degeneration with Alzheimer's disease based immunotherapies: anti-amyloid-β antibody attenuates pathologies in an age-related macular degeneration mouse model. Vision Res. 48, 339-345 (2008).
143. Faktorovich, E. G., Steinberg, R. H., Yasumura, D., Matthes, M. T. & LaVail, M. M. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature 347, 83-86 (1990).
144. Fuhrmann, S., Kirsch, M. & Hofmann, H. D. Ciliary neurotrophic factor promotes chick photoreceptor development in vitro. Development 121, 2695-2706 (1995).
145. Fuhrmann, S., Grabosch, K., Kirsch, M. & Hofmann, H. D. Distribution of CNTF receptor α protein in the central nervous system of the chick embryo. J. Comp. Neurol. 461, 111-122 (2003). (Pubitemid 36578600)
146. Tao, W. et al. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 43, 3292-3298 (2002).
147. LaVail, M. M. et al. Multiple growth factors, cytokines, and neurotrophins rescue photoreceptors from the damaging effects of constant light. Proc. Natl Acad. Sci. USA 89, 11249-11253 (1992).
148. Cayouette, M. & Gravel, C. Adenovirus-mediated gene transfer of ciliary neurotrophic factor can prevent photoreceptor degeneration in the retinal degeneration (rd) mouse. Hum. Gene Ther. 8, 423-430 (1997). (Pubitemid 27140545)
149. Cayouette, M., Behn, D., Sendtner, M., Lachapelle, P. & Gravel, C. Intraocular gene transfer of ciliary neurotrophic factor prevents death and increases responsiveness of rod photoreceptors in the retinal degeneration slow mouse. J. Neurosci. 18, 9282-9293 (1998). (Pubitemid 28512459)
150. Zhang, K. et al. Ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for treatment of geographic atrophy in age-related macular degeneration. Proc. Natl Acad. Sci. USA 108, 6241-6245 (2011).
151. Lambert, W. S., Ruiz, L., Crish, S. D., Wheeler, L. A. & Calkins, D. J. Brimonidine prevents axonal and somatic degeneration of retinal ganglion cell neurons. Mol. Neurodegener. 6, 4 (2011).
152. WoldeMussie, E., Ruiz, G., Wijono, M. & Wheeler, L. A. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest. Ophthalmol. Vis. Sci. 42, 2849-2855 (2001). (Pubitemid 33035282)
153. Krupin, T., Liebmann, J. M., Greenfield, D. S., Ritch, R. & Gardiner, S. A randomized trial of brimonidine versus timolol in preserving visual function: results from the low-pressure glaucoma treatment study. Am. J. Ophthalmol. 151, 671-681 (2011).
154. Drance, S. M., Schulzer, M., Thomas, B. & Douglas, G. R. Multivariate analysis in glaucoma. Use of discriminant analysis in predicting glaucomatous visual field damage. Arch. Ophthalmol. 99, 1019-1022 (1981). (Pubitemid 11070422)
155. Wolfs, R. C. et al. Genetic risk of primary open-angle glaucoma. Population-based familial aggregation study. Arch. Ophthalmol. 116, 1640-1645 (1998). (Pubitemid 29001963)
156. Wiggs, J. L. Genetic etiologies of glaucoma. Arch. Ophthalmol. 125, 30-37 (2007). (Pubitemid 46072373)
157. Stone, E. M. et al. Identification of a gene that causes primary open angle glaucoma. Science 275, 668-670 (1997). (Pubitemid 27061334)
158. Ramdas, W. D. et al. Common genetic variants associated with open-angle glaucoma. Hum. Mol. Genet. 20, 2464-2471 (2011).
159. Burdon, K. P. et al. Genome-wide association study identifies susceptibility loci for open angle glaucoma at TMCO1 and CDKN2B-AS1. Nature Genet. 43, 574-578 (2011).
160. Hietala, K., Forsblom, C., Summanen, P. & Groop, P. H. Heritability of proliferative diabetic retinopathy. Diabetes 57, 2176-2180 (2008).
161. Arar, N. H. et al. Heritability of the severity of diabetic retinopathy: the FIND-Eye study. Invest. Ophthalmol. Vis. Sci. 49, 3839-3845 (2008).
162. Wong, T. Y. et al. Diabetic retinopathy in a multi-ethnic cohort in the United States. Am. J. Ophthalmol. 141, 446-455 (2006).
163. Tong, Z. et al. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl Acad. Sci. USA 105, 6998-7003 (2008). (Pubitemid 351754519)
164. Chen, Y. et al. Assessing susceptibility to age-related macular degeneration with genetic markers and environmental factors. Arch. Ophthalmol. 129, 344-351 (2011).
165. Neale, B. M. et al. Genome-wide association study of advanced age-related macular degeneration identifies a role of the hepatic lipase gene (LIPC). Proc. Natl Acad. Sci. USA 107, 7395-7400 (2010).
166. Klaver, C. C. et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am. J. Hum. Genet. 63, 200-206 (1998). (Pubitemid 30428336)
167. Bainbridge, J. W. et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N. Engl. J. Med. 358, 2231-2239 (2008). (Pubitemid 351724452)
168. Maguire, A. M. et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248 (2008). (Pubitemid 351724453)
169. Cideciyan, A. V. et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc. Natl Acad. Sci. USA 105, 15112-15117 (2008).
170. Deng, W. T. et al. Tyrosine-mutant AAV8 delivery of human MERTK provides long-term retinal preservation in RCS rats. Invest. Ophthalmol. Vis. Sci. 53, 1895-1904 (2012).
171. Hughes, A. E. et al. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nature Genet. 38, 1173-1177 (2006). (Pubitemid 44470363)
172. Hageman, G. S. et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann. Med. 38, 592-604 (2006). (Pubitemid 46292019)
173. Du, H., Lim, S. L., Grob, S. & Zhang, K. Induced pluripotent stem cell therapies for geographic atrophy of age-related macular degeneration. Semin. Ophthalmol. 26, 216-224 (2011).
174. Zhang, K. & Ding, S. Stem cells and eye development. N. Engl. J. Med. 365, 370-372 (2011).
175. Kim, J. et al. Direct reprogramming of mouse fibroblasts to neural progenitors. Proc. Natl Acad. Sci. USA 108, 7838-7843 (2011).
176. Gouras, P., Kong, J. & Tsang, S. H. Retinal degeneration and RPE transplantation in Rpe65-/-mice. Invest. Ophthalmol. Vis. Sci. 43, 3307-3311 (2002).
177. Urtti, A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv. Drug Deliv. Rev. 58, 1131-1135 (2006).
178. Thrimawithana, T. R., Young, S., Bunt, C. R., Green, C. & Alany, R. G. Drug delivery to the posterior segment of the eye. Drug Discov. Today 16, 270-277 (2011).
179. Burnham, C. M. Encapsulated cell technology could prevent blindness. Drug Discov. Today 8, 146-147 (2003). (Pubitemid 36170270)
180. Tao, W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin. Biol. Ther. 6, 717-726 (2006).
181. Sieving, P. A. et al. Ciliary neurotrophic factor (CNTF) for human retinal degeneration: Phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc. Natl Acad. Sci. USA 103, 3896-3901 (2006). (Pubitemid 43376652)
182. Zhang, R. et al. Intravitreal cell-based production of glucagon-like peptide-1. Retina 31, 785-789 (2011).
183. Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nature Rev. Drug Discov. 9, 615-627 (2010).
184. Shi, J., Votruba, A. R., Farokhzad, O. C. & Langer, R. Nanotechnology in drug delivery and tissue engineering: from discovery to applications. Nano Lett. 10, 3223-3230 (2010).
185. Sultana, Y., Maurya, D. P., Iqbal, Z. & Aqil, M. Nanotechnology in ocular delivery: current and future directions. Drugs Today 47, 441-455 (2011).
186. Zhang, L. et al. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83, 761-769 (2008). (Pubitemid 351556021)
187. Yan, M. et al. A novel intracellular protein delivery platform based on single-protein nanocapsules. Nature Nanotechnol. 5, 48-53 (2010).
188. Gariano, R. F. & Gardner, T. W. Retinal angiogenesis in development and disease. Nature 438, 960-966 (2005). (Pubitemid 43093962)
189. Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nature Rev. Drug Discov. 8, 129-138 (2009).
190. du Toit, L. C., Pillay, V., Choonara, Y. E., Govender, T. & Carmichael, T. Ocular drug delivery-a look towards nanobioadhesives. Expert Opin. Drug Deliv. 8, 71-94 (2011).
191. Hu, C.-M. J. et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA 108, 10980-10985 (2011).
192. Weinreb, R. N. & Lindsey, J. D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43, 716-722 (2002). (Pubitemid 34187638)
193. Hiett, J. A. & Dockter, C. A. Topical carbonic anhydrase inhibitors: a new perspective in glaucoma therapy. Optom. Clin. 2, 97-112 (1992).
194. Nilsson, S. F. et al. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47, 4042-4049 (2006). (Pubitemid 46044322)
195. Krauss, A. H. et al. Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating prostaglandin F2α agonist, in preclinical models. Exp. Eye Res. 93, 250-255 (2011).
196. Choudhri S., Wand, M. & Shields, M. B. A comparison of dorzolamide-timolol combination versus the concomitant drugs. Am. J. Ophthalmol. 130, 832-833 (2000). (Pubitemid 32000869)
197. Craven, E. R. et al. Brimonidine and timolol fixed-combination therapy versus montherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J. Ocul. Pharmacol. Ther. 21, 337-338 (2005).
198. Pfeiffer, N. & the German Latanoprost Fixed Combination Study Group. A comparison of the fixed combination of latanoprost and timolol with its individual components. Graefe's Arch. Clin. Exp. Ophthalmol. 240, 893-899 (2002). (Pubitemid 36097111)
199. Higginbotham, E. J. et al. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch. Ophthalmol. 120, 915-922 (2002). (Pubitemid 34755544)
200. Barneby, H. S. et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am. J. Ophthalmol. 140, 1-7 (2005).
201. Schuman, J. S. et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 140, 242-250 (2005).
202. Hommer A & the Ganfort Investigators Group I. A double-masked, randomized, parallel comparison of a fixed combination of bimatoprost 0.03%/timolol 0.5% with non-fixed combination use in patients with glaucoma or ocular hypertension. Eur. J. Ophthalmol. 17, 53-62 (2007). (Pubitemid 46580599)
203. Rhiaume, M. A. & Vavvas, D. Pharmacologic vitreolysis. Semin. Ophthalmol. 25, 295-302 (2010).
204. Gandorfer, A. et al. Posterior vitreous detachment induced by microplasmin. Invest. Ophthalmol. Vis. Sci. 45, 641-647 (2004). (Pubitemid 38140525)
205. Pieramici, D. J. & Boyer, D. S. The phase III MIVI-TRUST clinical trial data: subgroup analysis of a single intravitreal injection of ocriplasmin in patients with full-thickness macular hole (Poster). In The Annu. Meeting of The Assoc. for Research in Vision and Ophthalmology (ARVO) (6-10 May 2012; Ft. Lauderdale, Florida, USA).